Table 4.
Combination of markers with morphometric variables to predict outcomes following liver transplantation for HCC
| Marker | Study, criterion name | Value for cut-off | HCC characteristic | 5-year RFS (%) | 5-year OS (%) |
|---|---|---|---|---|---|
| AFP | DuBay et al.,119 Toronto | <400 | hCC confined to the liver and no poor histologic differentiation | 66 | 70 |
| Toso et al.,120 Toso | ≤400 | Total tumor volume ≤115 cm3 | 68.0* | 74.6* | |
| Wan et al.121 | ≤400 | Tumor ≤10 cm, no vascular and extrahepatic invasions | 74.4 | 73.7 | |
| Duvoux et al.,122 French | ≤100 | Nodule diameters ≤3 cm, between 3-6 cm, or ≥6 cm | 66.6 | 69.9 | |
| PIVKA-II | Kaido et al.,123 Kyoto | ≤400 | Up to 10 hCCs with a diameter ≤5 cm | - | 82.0 |
| Ito et al.124 | ≤400 | Tumor size ≤10 cm | - | 86.7 | |
| Soejima et al.125 | ≤300 | Tumor size ≤5 cm | 93.8† | - | |
| AFP/PIVKA-II | Lee et al.,7 MoRAL | AFP and PIVKA-II derived score | Beyond Milan criteria | 66.3 | 86.0 |
| Todo et al.14 | AFP ≤200, PIVKA-II ≤100 | Milan criteria | 96.4 | - | |
| Shindoh et al.126 | AFP ≤250, PIVKA-II ≤450 | Tokyo criteria | 96.8 | - | |
| NLR/CRP | Na et al.18 | NLR < 6.0 and CRP < 1.0 | None | 96.8 | 84.0 |
HCC, hepatocellular carcinoma; RFS, recurrence-free survival; OS, overall survival; AFP, alpha-fetoprotein; PIVKA-II, prothrombin-induced by vitamin K absence or antagonist-II; NLR, neutrophil to lymphocyte ratio; CRP, c-reactive protein.
*
4-year;
†
3-year.